Historical volatility data included in the avdl stock forecast suggests average monthly swings of 6%, which traders may leverage through strategic entry points. It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Avadel Pharmaceuticals plc's ( NASDAQ:AVDL ) case, it's fantastic news for shareholders. Avadel Pharmaceuticals is a biotech company which is currently anticipating approval for FT218, a drug treating narcolepsy. Im not gonna go in depth on it cuz it really doesn’t matter for the swing I'm tryna do, but basically breakthrough therapies like FT218 are highly demanded by investors. Thus, Analyst consensus in the avdl stock forecast maintains an “Outperform” rating, underpinned by the company’s strong cash position and ability to fund continued R&D without dilution risk.
